A deeper dive with Dr. Ted Braun
Understanding the mechanisms of blood cancers
“The major barrier to leveraging [single cell RNA-seq] data is the intensive and expensive workflows, which limit analysis of large patient datasets. That’s where our collaboration with Scale Biosciences began. Processing more samples allows us to better delineate AML subtypes and understand underlying molecular mechanisms.”Dr. Theodore Braun Assistant Professor of Medicine, OHSU Knight Cancer Institute
Top-level highlights
>2.5M
Total cells in current multi-omic experimental plan
5
Omic modes of analysis
Hidden AML heterogeneity
By analyzing acute myeloid leukemia patients using Scale Bio's scRNA-seq technology, Dr. Braun's team discovered extensive heterogeneity within and across different AML subtypes that was completely missed by bulk transcriptomics, demonstrating how single-cell resolution is essential for capturing the true complexity of blood cancers.
Critical cancer marker detection
The large-scale approach detected SETBP1 oncogene overexpression in a primitive AML subtype that conventional flow cytometry and bulk RNA sequencing would have missed, revealing early disease markers that would have later been diagnosed as mixed-phenotype acute leukemia (MPAL).
Multiomic atlas of hematopoiesis
Profiled scRNA-seq, scATAC-seq, and scMET from healthy human bone marrow as a tool for understanding blood cancers.
Webinar snapshot
Ted's Exhibitor Theater Talk at AACR 2025
High throughput single-cell genomics enables the mechanistic characterization of blood cancers
Related customer stories
Single Cell Methylation
Transform your understanding of biology by exploring epigenetic complexity at a cellular level.
From vision to discovery: Researchers transforming biology through scale
Learn more about the researchers and their ambitious single cell projects.